HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor ...

HCW11-040 is a first-in-class pembrolizumab-based, tetra-valent immune checkpoint inhibitor designated as Company’s franchise ...

Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class ...

Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate ...